Dr. Barnes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Boston, MA 02114Phone+1 617-724-4000
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2005 - 2007
University of Illinois College of MedicineClass of 2004
Certifications & Licensure
MA State Medical License 2007 - 2026
NH State Medical License 2024 - 2024
ME State Medical License 2020 - 2021
Clinical Trials
- A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL Start of enrollment: 2014 Jun 01
Publications & Presentations
PubMed
- Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: Primary analysis of the ELM-1 study.Max S Topp, Matthew J Matasar, John N Allan, Stephen M Ansell, Jeffrey A Barnes
Blood. 2024-12-30 - Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis.Leon D Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, Jeremy S Abramson, Maria Martinez-Lage
American Journal of Hematology. 2024-12-01 - Delays in diagnosis in cutaneous T-cell lymphoma: A retrospective study on clinical course and time to death.Bethany Brumbaugh, Beatrix Thompson, Allison Holt, Joseph Ebriani, Katherine Perlman
Journal of the American Academy of Dermatology. 2024-11-01
Abstracts/Posters
- Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD EvaluationJeffrey A. Barnes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)Jeffrey A. Barnes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
